Home / Health / New Vaccine Aims to Reverse Immune System Aging
New Vaccine Aims to Reverse Immune System Aging
18 Jun
Summary
- A new vaccine trial targets worn-out T-cells to combat diseases.
- The jab aims to restore the immune system's ability to recognize threats.
- Success could offer a new treatment approach for immune-related diseases.
A groundbreaking clinical trial is set to investigate a new vaccine aimed at rejuvenating the human immune system. This innovative jab, developed by SenTcell and researchers at University College London (UCL) Medicine, targets exhausted T-cells, a critical component of immune defense that declines with age and chronic illness.
The therapy seeks to restore the immune system's youthful characteristics, enhancing its ability to recognize and combat threats such as cancer, HIV, and dementia. Dr. Alessio Lanna, founder of SenTcell, stated the goal is to establish immune rejuvenation as a novel treatment modality for diseases linked to immune aging and dysfunction.
Researchers are focusing on CD4+ T cells, vital for coordinating immune responses. The trial will involve adult participants with immune dysfunction, including those with immune aging and chronic viral infections. Participants will undergo detailed immune profiling to assess the therapy's effectiveness in restoring healthy immune function.
If successful, this immune rejuvenation strategy could revolutionize treatment by bolstering the immune system itself, rather than targeting individual pathogens or diseases. The program has received support through the MHRA's Innovative Licensing and Access Pathway, with trials anticipated to commence later this year.
